Kailera Therapeutics, Inc. (KLRA)

Kailera Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Total Valuation

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Nov 9, 2026	Dec 31, 2025	Dec 31, 2024
Market Capitalization	1,721	-	-
Market Cap Growth	-	-	-
Enterprise Value	693	-	-

Financial Efficiency

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Nov 9, 2026	Dec 31, 2025	Dec 31, 2024
Debt / Equity Ratio	0.01	0.02	0.00
Net Debt / Equity Ratio	-1.00	-1.01	-1.02
Net Debt / EBITDA Ratio	2.71	4.06	7.15
Net Debt / FCF Ratio	3.14	5.25	0.94
Quick Ratio	21.55	11.83	25.35
Current Ratio	21.84	12.02	25.70
Return on Equity (ROE)	-	-36.90%	-
Return on Assets (ROA)	-	-22.73%	-
Return on Capital Employed (ROCE)	-36.50%	-24.50%	-14.30%

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Nov 4, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 9, 2026

Data Sources Report a data error